Feature | February 04, 2013| Dave Fornell

Game-Changing Technologies to Watch in 2013

My job as editor of DAIC is to help readers keep tabs on the latest in cardiovascular technology and trends. With collaboration from my Editorial Advisory Board, we developed a 2013 editorial calendar based on several predictions on what will be the key game-changing technologies.  These were determined from observations at numerous cardiology meetings we attended and from needs or trends members of the board have seen in their own practices. Here are our top predictions:

• Fractional flow reserve (FFR) is becoming more popular because of sound clinical trial data that continues to be reinforced, its inclusion in treatment guidelines and for its potential to save money by reducing the number of stents implanted. Current iterations of the catheter-based technology can be time-consuming and require use of adenosine, which has limited adoption. A new method called IFR may greatly simplify, reduce time and eliminate the need for adenosine. A second technology showing great promise is computed tomography (CT)–FFR, which measures the FFR for all coronary vessel segments noninvasively and allows placement of virtual stents to measure their hemodynamic impact. 

• Stage 2 meaningful use requirements will greatly impact cardiovascular information systems (CVIS). Stage 2 calls for clinical decision support, which will likely be seen in the form of overlay software to double-check if appropriate use criteria is being followed and to red-flag instances when it is not. Other requirements call for simplified image sharing both inside and outside hospitals, and computerized physician order entry (CPOE). Patient participation is also required, possibly by having them access information or share clinical updates via website interfaces, especially in the case of heart failure and EP implantable device followups.

• New ICD technology with the new subcutaneous ICD systems offer a much simplified implant procedure and the potential to greatly reduce complications.  The results of the MADIT-RIT trial will likely make ICDs more effective by changing the way the devices are programmed. 

• Hemodynamic support devices are seeing a lot of movement with the introduction of a new 5 LPM percutaneous ventricular assist device (PVAD), a new trial examining a PVAD’s impact on infarct size, FDA review of intra-aortic balloon pumps, and the increasing use of mobile extracorporeal membrane oxygenation (ECMO) units, especially in the hybrid OR.

• Near-infrared spectroscopy intravascular imaging may offer a vulnerable plaque detection tool to preemptively stent potential STEMI lesions.  

• Renal denervation therapy has gone from a sideshow session at meetings into the mainstream, with major vendors now making investments. 

Several of these topics are covered in the Jan/Feb 2013 issue of DAIC.

Related Content

iSmartweaR, smart clothing, jIndustrial Technology Research Institute, ITRI, wearable heart monitoring

An example of an iSmartweaR shirt that can monitor patient vital signs without the need for electrode wires.

News | Wearable Sensors| October 24, 2016
October 24, 2016 — Conventional smart clothing uses conductive fibers or rubber as sensing electrodes, and cardiac el
medicare bundled cardiac payments, CMS cardiology payments
Feature | Business| October 24, 2016 | By John W. Meyer, MPH, FACHE
(Editor’s note: This is the second part of a two-part series on the proposed Medicare five-year demonstration for
bioresorbable stents, bioabsorbable stents, visualizing the Absorb BVS, dissolving stent, disappearing stent on IVUS and OCT

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system


Feature | Stents Bioresorbable| October 20, 2016 | Dave Fornell
There has been a lot of interest in the interventional community regarding the Abbott Absorb Bioresorbable Vascular S
Avinger, Pantheris atherectomy catheter, OCT, Lumivascular technology, expanded FDA indication, diagnostic imaging device
News | Atherectomy Devices| October 20, 2016
Avinger Inc. recently announced that the company has received expanded indications from the U.S. Food and Drug...
recall, alligator retrieval device, X-Celerator hydrophilic guidewire, UltraFlow flow directed micro catheters, Marathon flow directed micro catheters
News | Cath Lab| October 18, 2016
Medtronic plc announced last week that it has notified customers of a voluntary recall of certain lots of its Pipeline...
Inventory management, Cardinal, RFID inventory tracking, cath lab inventory
Sponsored Content | Whitepapers | Inventory Management| October 18, 2016
As healthcare moves into the era of bundled payments, providers need to be especially focused on ensuring delivery of
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices| October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
Medtronic, FDA approval, MRI, MR-conditional scanning, cardiac devices
Technology | EP Lab| October 13, 2016
Medtronic plc is the first company to receive U.S. Food and Drug Administration (FDA) approval for its suite of cardiac...
Overlay Init